Amneal Pharmaceuticals Inc (AMRX) Stock Analysis
Verdict: HOLD
Robust specialty drug execution drives EPS inflection toward $1.01 in 2026, though a $2.43B net debt load caps valuation expansion.
Investment score: 62/100
Analysis as of
Is Amneal Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
Amneal Pharmaceuticals exhibits powerful earnings momentum and improving margins, but high leverage ($2.43B net debt) and proximity to its 52-week high make HOLD the optimal rating.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 52/100 (weight 15%)
- Technical Momentum: 82/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Amneal Pharmaceuticals Inc opportunities and risks
What speaks for AMRX
- Consistent Earnings Outperformance Trend
What speaks against AMRX
- Elevated Net Debt Burden and Negative Book Equity
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AMRX | 37.1x | 1.9x | 13.1x | 39.3% | 5.0% | 1.4% |
| TARS | n/a | 5.6x | n/a | 90.6% | -7.7% | 1.8% |
| MBX | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.8% |
| GPCR | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.0% |
| HRMY | 13.6x | 2.6x | 7.5x | 75.4% | 18.9% | 14.4% |
| SUPN | n/a | 3.0x | n/a | 88.1% | -13.2% | 0.8% |
| Peer median | n/a | 2.6x | n/a | 75.4% | 0.0% | 0.8% |
Frequently asked questions about Amneal Pharmaceuticals Inc (AMRX)
Is AMRX stock a good investment?
The TradeMates model rates Amneal Pharmaceuticals Inc as HOLD with an investment score of 62/100. Amneal Pharmaceuticals exhibits powerful earnings momentum and improving margins, but high leverage ($2.43B net debt) and proximity to its 52-week high make HOLD the optimal rating. This is algorithmic model output, not personal investment advice.
Is AMRX stock a buy?
The TradeMates model verdict for AMRX is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.